Department of Functional Sciences, Faculty of Pharmacy, Universidade do Oeste Paulista, Presidente Prudente, Sao Paulo, Brasil.
Department of Functional Sciences, Faculty of Medicine, Universidade do Oeste Paulista, Presidente Prudente, Sao Paulo, Brasil.
Nutr Rev. 2022 Jan 10;80(2):157-164. doi: 10.1093/nutrit/nuab017.
Inflammatory bowel diseases are chronic, relapsing diseases that compromise life quality and expectancy. The increased incidence and prevalence of these diseases reinforce the need for research on prevention, therapy, and management innovations. Synbiotics (ie, probiotic plus prebiotic combinations) are suggested as an alternative or complementary therapy to conventional treatments for inflammatory bowel disease.
The aim for this systematic review was to gather and analyze data from randomized controlled trials to provide more information to increase the current evidence level about the safety and efficacy of synbiotic use as a supplemental treatment for ulcerative colitis.
Searches were performed in the Medline, Science Direct, Scielo, Scopus, and Embase databases between January 2017 and March 2019, using the keywords "colitis" and "synbiotics".
The data extraction method performed for each trial was based on the recommendations of the Consolidated Standards of Reporting Trials for randomized clinical trials. The trials included in this meta-analysis presented low risk of bias, based on the Cochrane Handbook for Systematic Reviews of Interventions guidelines.
The results demonstrated that synbiotics significantly improved colonic endoscopic and histologic scores, the Clinical Activity Index, serum C-reactive protein levels, intestinal microbiota, Bowel Habits Index, and levels of messenger RNAs, tumor necrosis factor-α, interleukin-1α, interleukin-10, and myeloperoxidase in the patients. In addition, the use of synbiotics increased probiotic microorganisms, reduced proinflammatory colonic cytokines, and elevated anti-inflammatory cytokines.
Therefore, the results of this meta-analysis reinforce the evidence that synbiotics provide benefits to patients when used as an alternative or complementary therapy for those with ulcerative colitis.
炎症性肠病是一种慢性、复发性疾病,会影响生活质量和预期寿命。这些疾病的发病率和患病率不断上升,这就需要加强对预防、治疗和管理创新的研究。益生菌与益生元联合使用(即合生素)被认为是炎症性肠病传统治疗的一种替代或补充疗法。
本系统评价的目的是收集和分析随机对照试验的数据,提供更多信息,以提高合生素作为溃疡性结肠炎辅助治疗的安全性和有效性的现有证据水平。
2017 年 1 月至 2019 年 3 月期间,在 Medline、Science Direct、Scielo、Scopus 和 Embase 数据库中使用“结肠炎”和“合生素”等关键词进行了检索。
针对每项试验,提取数据的方法均基于对随机临床试验的统一报告标准的建议。本荟萃分析纳入的试验基于 Cochrane 系统评价干预措施手册,被认为具有低偏倚风险。
结果表明,合生素可显著改善结肠内镜和组织学评分、临床活动指数、血清 C 反应蛋白水平、肠道微生物群、排便习惯指数以及信使 RNA、肿瘤坏死因子-α、白细胞介素-1α、白细胞介素-10 和髓过氧化物酶水平。此外,合生素的使用增加了益生菌微生物,减少了促炎结肠细胞因子,提高了抗炎细胞因子。
因此,这项荟萃分析的结果进一步证实了合生素作为溃疡性结肠炎的替代或补充治疗方法可为患者带来益处的证据。